New HIV vaccine enters human testing in africa
NCT ID NCT06617091
Summary
This is an early-stage study to test the safety and immune response of a new HIV vaccine candidate. It will enroll 120 healthy adults in Southern Africa, including people living with HIV who have their virus well-controlled with medication. The main goal is to see if the vaccine is safe and if it triggers an immune response that could potentially help prevent or control HIV.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
AHRI
RECRUITINGMtubatuba, KwaZulu-Natal, South Africa
-
DTHF
RECRUITINGCape Town, Western Cape, South Africa
-
Mutala
RECRUITINGHarare, Harare, Zimbabwe
Conditions
Explore the condition pages connected to this study.